A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9)

Phase 3 study (TRIUMPH-9), condition: Obesity, Overweight. The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks. Enrolment: 600 participants. Status: active, not recruiting. No topline or peer-reviewed results are verified for publication on this Record for this study — registry facts only.